{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:18:42Z","timestamp":1786119522507,"version":"build-2736575974"},"reference-count":23,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,8,27]]},"DOI":"10.1097\/tp.0b013e3181e72837","type":"journal-article","created":{"date-parts":[[2010,6,22]],"date-time":"2010-06-22T06:05:20Z","timestamp":1277186720000},"page":"407-411","source":"Crossref","is-referenced-by-count":10,"title":["Treatment of Hepatitis C in Renal Transplantation Candidates: A Single-Center Experience"],"prefix":"10.1097","volume":"90","author":[{"given":"T.","family":"Werner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bashar","family":"Aqel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vijayan","family":"Balan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Byrne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Carey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Douglas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond L.","family":"Heilman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Rakela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin","family":"Mekeel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunam","family":"Reddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugo E.","family":"Vargas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-13-20210129","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1111\/j.1572-0241.2008.01981.x","article-title":"HCV in patients with end-stage renal disease.","volume":"103","author":"Okoh","year":"2008","journal-title":"Am J Gastroenterol"},{"key":"R2-13-20210129","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.jhep.2008.06.003","article-title":"Hepatitis C virus and kidney disease.","volume":"49","author":"Martin","year":"2008","journal-title":"J Hepatol"},{"key":"R3-13-20210129","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1002\/hep.510290123","article-title":"Impact of hepatitis B and C virus on kidney transplantation outcome.","volume":"29","author":"Mathurin","year":"1999","journal-title":"Hepatology"},{"key":"R4-13-20210129","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1046\/j.1365-2036.2003.01780.x","article-title":"Meta-analysis: Interferon for the treatment of chronic hepatitis C in dialysis patients.","volume":"18","author":"Fabrizi","year":"2003","journal-title":"Aliment Pharmacol Ther"},{"key":"R5-13-20210129","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1053\/jhep.2002.34613","article-title":"Hepatitis C infection and the patient with end-stage renal disease.","volume":"36","author":"Fabrizi","year":"2002","journal-title":"Hepatology"},{"key":"R6-13-20210129","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1080\/08860220701813368","article-title":"Long-term efficacy of pegylated interferon alpha-2a in HCV-positive hemodialysis patients.","volume":"30","author":"Ucmak","year":"2008","journal-title":"Ren Fail"},{"key":"R7-13-20210129","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1093\/ndt\/gfi231","article-title":"Randomized trial of pegylated interferon alpha-2b monotherapy in haemodialysis patients with chronic hepatitis C.","volume":"21","author":"Russo","year":"2006","journal-title":"Nephrol Dial Transplant"},{"key":"R8-13-20210129","doi-asserted-by":"crossref","first-page":"2444","DOI":"10.1056\/NEJMct061675","article-title":"Peginterferon and ribavirin for chronic hepatitis C.","volume":"355","author":"Hoofnagle","year":"2006","journal-title":"N Engl J Med"},{"key":"R9-13-20210129","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1136\/gut.2007.133884","article-title":"Pegylated interferon alpha-2a versus standard interferon alpha-2a for treatment-naive dialysis patients with chronic hepatitis C: A randomised study.","volume":"57","author":"Liu","year":"2008","journal-title":"Gut"},{"key":"R10-13-20210129","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1093\/ndt\/16.1.193","article-title":"Safety of interferon and ribavirin therapy in haemodialysis patients with chronic hepatitis C: Results of a pilot study.","volume":"16","author":"Tan","year":"2001","journal-title":"Nephrol Dial Transplant"},{"key":"R11-13-20210129","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1097\/MCG.0b013e318180803a","article-title":"HCV Response in patients with end stage renal disease treated with combination pegylated interferon alpha-2a and ribavirin.","volume":"43","author":"Hakim","year":"2009","journal-title":"J Clin Gastroenterol"},{"key":"R12-13-20210129","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1111\/j.1440-1746.2005.04008.x","article-title":"Efficacy and tolerability of pegylated-interferon alpha-2a in hemodialysis patients with chronic hepatitis C.","volume":"21","author":"Kokoglu","year":"2006","journal-title":"J Gastroenterol Hepatol"},{"key":"R13-13-20210129","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1002\/hep.22545","article-title":"Treatment of chronic hepatitis C in hemodialysis patients.","volume":"48","author":"Berenguer","year":"2008","journal-title":"Hepatology"},{"key":"R14-13-20210129","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1016\/j.transproceed.2007.07.013","article-title":"Preliminary results of treatment with pegylated interferon alpha 2A for chronic hepatitis C virus in kidney transplant candidates on hemodialysis.","volume":"39","author":"Casanovas-Taltavull","year":"2007","journal-title":"Transplant Proc"},{"key":"R15-13-20210129","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1002\/hep.22759","article-title":"Diagnosis, management, and treatment of hepatitis C: An update.","volume":"49","author":"Ghany","year":"2009","journal-title":"Hepatology"},{"key":"R16-13-20210129","first-page":"794","article-title":"Analysis of safety and efficacy of pegylated-interferon alpha-2a in hepatitis C virus positive hemodialysis patients: Results from a large, multicenter audit.","volume":"19","author":"Covic","year":"2006","journal-title":"J Nephrol"},{"key":"R17-13-20210129","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1681\/ASN.V9122344","article-title":"Pharmacokinetics of alphaIFN-2b in chronic hepatitis C virus patients undergoing chronic hemodialysis or with normal renal function: Clinical implications.","volume":"9","author":"Rostaing","year":"1998","journal-title":"J Am Soc Nephrol"},{"issue":"suppl 1","key":"R18-13-20210129","first-page":"17","article-title":"The clinical pharmacology of ribavirin.","volume":"19","author":"Glue","year":"1999","journal-title":"Semin Liver Dis"},{"key":"R19-13-20210129","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/S0272-6386(03)00828-X","article-title":"Hepatitis C and renal disease: An update.","volume":"42","author":"Meyers","year":"2003","journal-title":"Am J Kidney Dis"},{"key":"R20-13-20210129","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1111\/j.1365-2893.2005.00680.x","article-title":"Pegylated interferon and ribavirin treatment for hepatitis C in haemodialysis patients.","volume":"13","author":"Bruchfeld","year":"2006","journal-title":"J Viral Hepat"},{"key":"R21-13-20210129","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1093\/ndt\/gfg209","article-title":"Interferon and ribavirin treatment in patients with hepatitis C-associated renal disease and renal insufficiency.","volume":"18","author":"Bruchfeld","year":"2003","journal-title":"Nephrol Dial Transplant"},{"key":"R22-13-20210129","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1053\/ajkd.2001.28590","article-title":"Decreased serum aminotransferase activity in patients with chronic renal failure: Impact on the detection of viral hepatitis.","volume":"38","author":"Fabrizi","year":"2001","journal-title":"Am J Kidney Dis"},{"key":"R23-13-20210129","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1002\/hep.510270505","article-title":"Factors associated with serum alanine transaminase activity in healthy subjects: Consequences for the definition of normal values, for selection of blood donors, and for patients with chronic hepatitis C. MULTIVIRC Group.","volume":"27","author":"Piton","year":"1998","journal-title":"Hepatology"}],"container-title":["Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00007890-201008270-00013","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T18:29:11Z","timestamp":1786040951000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00007890-201008270-00013"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,8,27]]},"references-count":23,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2010]]}},"URL":"https:\/\/doi.org\/10.1097\/tp.0b013e3181e72837","relation":{},"ISSN":["0041-1337"],"issn-type":[{"value":"0041-1337","type":"print"}],"subject":[],"published":{"date-parts":[[2010,8,27]]}}}